Advertisement

Topics

Lilly Stays Committed To Alzheimer's, Including Amyloid Hypothesis, Despite Many Failures

18:57 EDT 13 Jun 2018 | SCRIP

The failure of BACE inhibitor lanabecestat was the latest setback in Lilly's Alzheimer's pipeline, but the company has been working...

      

Related Stories

 

Original Article: Lilly Stays Committed To Alzheimer's, Including Amyloid Hypothesis, Despite Many Failures

NEXT ARTICLE

More From BioPortfolio on "Lilly Stays Committed To Alzheimer's, Including Amyloid Hypothesis, Despite Many Failures"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Alzheimer's Disease
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase  'plaques' and 'tangles' (mis-folded proteins) form in the brain. People with Al...